Items where Funder is Tillotts Pharma AG.

Reference not given

Goodoory, VC orcid.org/0000-0001-9483-5604, Ng, CE, Black, CJ et al. (1 more author) (2022) Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Alimentary Pharmacology & Therapeutics, 56 (1). pp. 110-120. ISSN 0269-2813

Goodoory, VC orcid.org/0000-0001-9483-5604, Ng, CE, Black, CJ et al. (1 more author) (2022) Impact of Rome IV Irritable Bowel Syndrome on Work and Activities of Daily Living. Alimentary Pharmacology and Therapeutics (AP&T), 56 (5). pp. 844-856. ISSN 0269-2813